Candriam S.C.A. Veracyte, Inc. Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
A detailed history of Candriam S.C.A. transactions in Veracyte, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 231,676 shares of VCYT stock, worth $9.96 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
231,676
Previous 670,937
65.47%
Holding current value
$9.96 Million
Previous $14.5 Million
45.78%
% of portfolio
0.05%
Previous 0.09%
Shares
15 transactions
Others Institutions Holding VCYT
# of Institutions
308Shares Held
81.8MCall Options Held
134KPut Options Held
13.3K-
Black Rock Inc. New York, NY7.79MShares$335 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.75MShares$333 Million0.0% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI5.02MShares$216 Million0.27% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl4.92MShares$211 Million1.59% of portfolio
-
Wellington Management Group LLP Boston, MA4.23MShares$182 Million0.03% of portfolio
About VERACYTE, INC.
- Ticker VCYT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,575,904
- Market Cap $3.08B
- Description
- Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...